Pulse Biosciences, Inc
PLSE
Positions held
Your positionsPLSE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Pulse Biosciences operates in the innovative medical instruments sector, focusing on unique technologies that could revolutionize treatment options.
- Revenue increased by 8% compared to the prior quarter, reaching $0.434 million.
- Gross margin improved significantly to 37.1%, up from 7.7% in the previous quarter.
- The company faces intense competition in the medical instruments industry, which may hinder its growth potential.
- Operating margin remains severely negative at -5823%, indicating ongoing financial struggles.
- Net income for the latest quarter was -24.657 million, reflecting continued losses.
Fundamentals
| Market cap | $3.56B | Enterprise value | $3.47B | Trailing P/E | — | Forward P/E | -42.72 |
| PEG | — | Price / book | 35.57 | Beta | 1.57 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.3% | Operating margin | -58.2% |
| Profit margin | 0.0% | ROE | -78.5% | ROA | -44.3% | Debt / equity | 0.07 |
| Current ratio | 9.63 | Free cash flow | -$34.29M | Analyst recommendation | strong_buy | Mean target | $56.50 |
| 52w high | $58.90 | 52w low | $12.56 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.4M | $0.4M | $0.3M | $0.1M | $0.0M | — |
| Op margin | -5823.0% | -4775.6% | -6914.0% | -23682.6% | — | — |
| Net income | -$24.7M | -$18.6M | -$17.4M | -$19.4M | -$19.2M | — |
| Gross margin | 37.1% | 7.7% | 1.5% | -224.4% | — | — |
| Gross profit | $0.2M | $0.0M | $0.0M | -$0.2M | $0.0M | — |
| Operating income | -$25.3M | -$19.1M | -$18.3M | -$20.4M | -$20.3M | — |
- Revenue +8% vs prior quarter ($0.4M vs $0.4M).
- Gross margin 37.1% (was 7.7% prior quarter).
- Operating margin compressed to -5823%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.3M | $0.0M | $0.0M | $0.7M | — |
| Op margin | -21982.6% | — | — | -8293.9% | — |
| Net income | -$72.8M | -$53.6M | -$42.2M | -$58.5M | — |
| Gross margin | -54.0% | — | — | -1606.3% | — |
| Gross profit | -$0.2M | $0.0M | $0.0M | -$11.2M | — |
| Operating income | -$76.9M | -$56.3M | -$43.6M | -$58.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
2026-10-07 · Pulse Biosciences Reaches Enrollment Target in Nanopulse-AF Study
2026-10-03 · Pulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA Data
2026-09-23 · BTIG Initiates Pulse Biosciences at Buy With $70 Price Target
2026-09-15 · Pulse Biosciences Completes Enrollment in 100-Patient Thyroid Nodule Study
2026-09-09 · Why Pulse Biosciences Stock Popped Today
2026-09-04 · Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-18 · Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-16 · Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns
2026-08-16 · Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Price (daily)
Full chart · RSI · MACD · patterns